SK286945B6 - Expresný systém faktora VIII - Google Patents

Expresný systém faktora VIII Download PDF

Info

Publication number
SK286945B6
SK286945B6 SK792-2001A SK7922001A SK286945B6 SK 286945 B6 SK286945 B6 SK 286945B6 SK 7922001 A SK7922001 A SK 7922001A SK 286945 B6 SK286945 B6 SK 286945B6
Authority
SK
Slovakia
Prior art keywords
leu
ser
protein
factor viii
glu
Prior art date
Application number
SK792-2001A
Other languages
English (en)
Slovak (sk)
Other versions
SK7922001A3 (en
Inventor
Myung-Sam Cho
Sham-Yuen Chan
William Kelsey
Helena Yee
Original Assignee
Bayer Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Corporation filed Critical Bayer Corporation
Publication of SK7922001A3 publication Critical patent/SK7922001A3/sk
Publication of SK286945B6 publication Critical patent/SK286945B6/sk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/028—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a herpesvirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Compounds Of Unknown Constitution (AREA)
SK792-2001A 1998-12-10 1999-12-08 Expresný systém faktora VIII SK286945B6 (sk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/209,916 US6358703B1 (en) 1998-12-10 1998-12-10 Expression system for factor VIII
PCT/US1999/029169 WO2000034505A1 (en) 1998-12-10 1999-12-08 Expression system for factor viii

Publications (2)

Publication Number Publication Date
SK7922001A3 SK7922001A3 (en) 2002-01-07
SK286945B6 true SK286945B6 (sk) 2009-08-06

Family

ID=22780858

Family Applications (1)

Application Number Title Priority Date Filing Date
SK792-2001A SK286945B6 (sk) 1998-12-10 1999-12-08 Expresný systém faktora VIII

Country Status (26)

Country Link
US (10) US6358703B1 (de)
EP (1) EP1137797B1 (de)
JP (1) JP4240818B2 (de)
KR (1) KR100616028B1 (de)
AT (1) ATE412765T1 (de)
AU (1) AU761801B2 (de)
BG (1) BG65431B1 (de)
BR (1) BRPI9916069B8 (de)
CA (1) CA2354845C (de)
CZ (1) CZ302330B6 (de)
DE (1) DE69939839D1 (de)
DK (1) DK1137797T3 (de)
ES (1) ES2315026T3 (de)
HU (1) HU228489B1 (de)
IL (2) IL143353A0 (de)
NO (1) NO329544B1 (de)
NZ (1) NZ512234A (de)
PL (1) PL200676B1 (de)
PT (1) PT1137797E (de)
RO (1) RO121604B1 (de)
RU (1) RU2249041C2 (de)
SI (1) SI20644B (de)
SK (1) SK286945B6 (de)
TR (1) TR200101592T2 (de)
UA (1) UA77383C2 (de)
WO (1) WO2000034505A1 (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6475725B1 (en) 1997-06-20 2002-11-05 Baxter Aktiengesellschaft Recombinant cell clones having increased stability and methods of making and using the same
US6180108B1 (en) * 1998-12-10 2001-01-30 Bayer Corporation Vectors having terminal repeat sequence of Epstein-Barr virus
US6358703B1 (en) 1998-12-10 2002-03-19 Bayer Corporation Expression system for factor VIII
MXPA02009221A (es) * 2000-03-22 2005-07-25 Octagene Gmbh Produccion de factores de coagulacion sanguineo recombinantes en lineas celular humanas.
WO2002103024A2 (en) * 2001-06-14 2002-12-27 The Scripps Research Institute Stabilized proteins with engineered disulfide bonds
AU2004215912B2 (en) 2003-02-26 2009-03-26 Nektar Therapeutics Polymer-factor VIII moiety conjugates
US7485291B2 (en) * 2003-06-03 2009-02-03 Cell Genesys, Inc. Compositions and methods for generating multiple polypeptides from a single vector using a virus derived peptide cleavage site, and uses thereof
WO2005017149A1 (en) * 2003-06-03 2005-02-24 Cell Genesys, Inc. Compositions and methods for enhanced expression of recombinant polypeptides from a single vector using a peptide cleavage site
AU2005302516A1 (en) * 2004-10-29 2006-05-11 Centocor, Inc. Chemically defined media compositions
DK1824988T3 (en) 2004-11-12 2017-08-07 Bayer Healthcare Llc LOCATION-SPECIFIC MODIFICATION OF FVIII
AR058568A1 (es) 2005-12-20 2008-02-13 Bristol Myers Squibb Co Metodos para producir una composicion con moleculas ctla4-ig a partir de un medio de cultivo
ES2439641T3 (es) 2005-12-20 2014-01-24 Bristol-Myers Squibb Company Composiciones y procedimientos de producción de una composición
US9359629B2 (en) 2007-12-27 2016-06-07 Baxalta Incorporated Cell culture processes
KR101005967B1 (ko) * 2008-04-12 2011-01-05 (주)셀트리온 우수한 재조합 단백질을 생산하기 위한 인간 숙주 세포
EP2304046A4 (de) * 2008-06-25 2011-11-23 Bayer Healthcare Llc Faktor-viii-muteine mit reduzierter immunogenität
RU2011110459A (ru) 2008-08-21 2012-09-27 Октафарма АГ (CH) Рекомбинантно полученный человеческий фактор viii и ix
KR20110073434A (ko) * 2008-09-03 2011-06-29 옥타파마 아게 재조합에 의해 제조된 인자 ⅷ을 위한 신규한 보호 조성물
US20110046060A1 (en) 2009-08-24 2011-02-24 Amunix Operating, Inc., Coagulation factor IX compositions and methods of making and using same
DK3178835T3 (da) 2009-02-03 2019-06-24 Amunix Pharmaceuticals Inc Forlængede rekombinante polypeptider og sammensætninger omfattende samme
US20120142593A1 (en) * 2009-03-24 2012-06-07 Bayer Healthcare Llc Factor VIII Variants and Methods of Use
US20110150843A1 (en) * 2009-10-30 2011-06-23 National Institute Of Immunology Method for the therapeutic correction of hemophilia a by transplanting bone marrow cells
US20130017997A1 (en) * 2010-08-19 2013-01-17 Amunix Operating Inc. Factor VIII Compositions and Methods of Making and Using Same
CN103517919B (zh) * 2011-05-13 2016-11-16 欧克塔医药公司 在重组fviii的生产中提高真核细胞生产率的方法
PL2804623T3 (pl) 2012-01-12 2020-03-31 Bioverativ Therapeutics Inc. Chimeryczne polipeptydy czynnika viii i ich zastosowania
BR112014020694A2 (pt) 2012-02-15 2018-05-08 Amunix Operating Inc. proteína de fusão do fator viii compreendendo polipeptídeo do fator viii fusionado a polipeptí-deo recombinante estendido (xten) e seu método de fabricação, ácido nucleico, vetores, célula hospedeira, bem como composição farmacêutica e seu uso no tratamento de coagulopatia, episódio de hemorragia e hemofilia a
AU2013204636B2 (en) 2012-02-15 2016-04-14 Bioverativ Therapeutics Inc. Recombinant Factor VIII proteins
TWI667255B (zh) 2013-08-14 2019-08-01 美商生物化學醫療公司 因子ｖｉｉｉ－ｘｔｅｎ融合物及其用途
RS63583B1 (sr) 2014-01-10 2022-10-31 Bioverativ Therapeutics Inc Himerni proteini faktora viii i njihova upotreba
TWI741992B (zh) 2015-08-03 2021-10-11 美商百歐維拉提夫治療公司 因子ｉｘ融合蛋白以及其製備及使用方法
EA201892347A1 (ru) 2016-04-15 2019-04-30 Баксалта Инкорпорейтед Способ и устройство для предоставления фармакокинетической схемы дозирования лекарственных препаратов
JP2019532019A (ja) 2016-07-22 2019-11-07 ネクター セラピューティクス オキシム含有リンケージを有する第ｖｉｉｉ因子部分のコンジュゲート
US10896749B2 (en) 2017-01-27 2021-01-19 Shire Human Genetic Therapies, Inc. Drug monitoring tool
WO2019055717A1 (en) * 2017-09-13 2019-03-21 Evolve Biosystems, Inc. OLIGOSACCHARIDE COMPOSITIONS AND THEIR USE DURING THE TRANSIENT PHASES OF INTESTINAL MICROBIOMA OF A MAMMALIAN
KR20190086269A (ko) * 2018-01-12 2019-07-22 재단법인 목암생명과학연구소 체내 지속형 재조합 당단백질 및 이의 제조방법
MX2020012397A (es) 2018-05-18 2021-04-12 Bioverativ Therapeutics Inc Metodos de tratamiento de la hemofilia a.
CN113301911A (zh) * 2018-10-23 2021-08-24 费城儿童医院 用于调节因子viii功能的组合物和方法

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6045849B2 (ja) * 1980-08-25 1985-10-12 林原 健 ヒトエリトロポエチンの製造方法
US4766075A (en) * 1982-07-14 1988-08-23 Genentech, Inc. Human tissue plasminogen activator
GB8308235D0 (en) * 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4757006A (en) * 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
US4703008A (en) * 1983-12-13 1987-10-27 Kiren-Amgen, Inc. DNA sequences encoding erythropoietin
KR890002004B1 (ko) * 1984-01-11 1989-06-07 가부시끼 가이샤 도오시바 지폐류 판별장치
US4965199A (en) * 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
US4970300A (en) * 1985-02-01 1990-11-13 New York University Modified factor VIII
ES8801674A1 (es) * 1985-04-12 1988-02-16 Genetics Inst Un procedimiento para la preparacion de una proteina que presenta actividad procoagulante.
US5198349A (en) * 1986-01-03 1993-03-30 Genetics Institute, Inc. Method for producing factor VIII:C and analogs
EP0254076B1 (de) * 1986-07-11 1991-05-08 Miles Inc. Herstellung von rekombinantem Protein
GB2197321B (en) 1986-09-12 1990-10-03 Genentech Inc Method and vectors for obtaining continuous production of heterologous protein in a eukaryotic host cell line
IE69026B1 (en) * 1987-06-12 1996-08-07 Immuno Ag Novel proteins with factor VIII activity process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
SE465222C5 (sv) 1989-12-15 1998-02-10 Pharmacia & Upjohn Ab Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning
US5661008A (en) * 1991-03-15 1997-08-26 Kabi Pharmacia Ab Recombinant human factor VIII derivatives
US5859204A (en) 1992-04-07 1999-01-12 Emory University Modified factor VIII
EP0629700A3 (de) * 1993-06-10 1995-02-15 Miles Inc Vektor und Zelllinien von Säugetieren, die eine erhöhte Produktivität aufweisen.
US5952198A (en) * 1995-05-04 1999-09-14 Bayer Corporation Production of recombinant Factor VIII in the presence of liposome-like substances of mixed composition
DE19517194A1 (de) * 1995-05-11 1996-11-14 Giesecke & Devrient Gmbh Vorrichtung und Verfahren zur Prüfung von Blattgut, wie z.B. Banknoten oder Wertpapiere
MX9504215A (es) 1995-10-05 1997-04-30 Inst Politecnico Nacional Procedimiento mejorado para la purificacion de oligopeptidos con pesos moleculares de 1000 a 10,000 daltones, a partir de estractos leucocitos y su presentacion farmaceutica.
US5922959A (en) * 1996-10-15 1999-07-13 Currency Systems International Methods of measuring currency limpness
US5923413A (en) * 1996-11-15 1999-07-13 Interbold Universal bank note denominator and validator
US5804420A (en) * 1997-04-18 1998-09-08 Bayer Corporation Preparation of recombinant Factor VIII in a protein free medium
AU735763B2 (en) * 1997-12-05 2001-07-12 Immune Response Corporation, The Novel vectors and genes exhibiting increased expression
US6040584A (en) * 1998-05-22 2000-03-21 Mti Corporation Method and for system for detecting damaged bills
US6528286B1 (en) * 1998-05-29 2003-03-04 Genentech, Inc. Mammalian cell culture process for producing glycoproteins
US6180108B1 (en) * 1998-12-10 2001-01-30 Bayer Corporation Vectors having terminal repeat sequence of Epstein-Barr virus
US6358703B1 (en) * 1998-12-10 2002-03-19 Bayer Corporation Expression system for factor VIII
US6136599A (en) * 1998-12-10 2000-10-24 Bayer Corporation Human hybrid host cell for mammalian gene expression

Also Published As

Publication number Publication date
EP1137797B1 (de) 2008-10-29
BRPI9916069B8 (pt) 2021-05-25
US20130267468A1 (en) 2013-10-10
NO20012718D0 (no) 2001-06-01
HU228489B1 (en) 2013-03-28
US8207117B2 (en) 2012-06-26
BG105567A (en) 2002-03-29
EP1137797A1 (de) 2001-10-04
WO2000034505A1 (en) 2000-06-15
US20130143818A1 (en) 2013-06-06
CA2354845C (en) 2008-08-12
CZ302330B6 (cs) 2011-03-16
US20170267745A1 (en) 2017-09-21
DK1137797T3 (da) 2009-02-23
DE69939839D1 (de) 2008-12-11
BR9916069A (pt) 2001-09-04
AU2170100A (en) 2000-06-26
PL349284A1 (en) 2002-07-15
HUP0200558A2 (en) 2002-06-28
JP2002531137A (ja) 2002-09-24
US20030077752A1 (en) 2003-04-24
US20020102730A1 (en) 2002-08-01
US6358703B1 (en) 2002-03-19
PT1137797E (pt) 2008-12-26
US9249209B2 (en) 2016-02-02
HUP0200558A3 (en) 2004-11-29
US20090036358A1 (en) 2009-02-05
SK7922001A3 (en) 2002-01-07
RO121604B1 (ro) 2007-12-28
US20160115219A1 (en) 2016-04-28
CA2354845A1 (en) 2000-06-15
BG65431B1 (bg) 2008-07-31
UA77383C2 (uk) 2006-12-15
NO20012718L (no) 2001-06-01
ATE412765T1 (de) 2008-11-15
SI20644B (sl) 2009-04-30
KR100616028B1 (ko) 2006-08-28
IL143353A0 (en) 2002-04-21
TR200101592T2 (tr) 2001-11-21
JP4240818B2 (ja) 2009-03-18
US20110144025A1 (en) 2011-06-16
US20020115152A1 (en) 2002-08-22
SI20644A (sl) 2002-02-28
IL143353A (en) 2010-12-30
RU2249041C2 (ru) 2005-03-27
NO329544B1 (no) 2010-11-08
US7459525B2 (en) 2008-12-02
EP1137797A4 (de) 2005-06-22
BRPI9916069B1 (pt) 2016-08-02
CZ20012024A3 (cs) 2001-10-17
US8945869B2 (en) 2015-02-03
AU761801B2 (en) 2003-06-12
ES2315026T3 (es) 2009-03-16
KR20020013481A (ko) 2002-02-20
US9650431B2 (en) 2017-05-16
NZ512234A (en) 2002-12-20
PL200676B1 (pl) 2009-01-30

Similar Documents

Publication Publication Date Title
SK286945B6 (sk) Expresný systém faktora VIII
EP0506757B2 (de) Rekombinanter abkömmling des menschlichen faktors iii
WO2008135498A2 (en) Prevention of protein degradation in mammalian cell cultures
KR20040047698A (ko) 변형된 ｃＤＮＡ 인자 Ⅷ 및 이의 유도체
JP2008522589A (ja) 組換えタンパク質の発現のための方法及び材料
KR20210100661A (ko) 인자 ix를 발현하는 렌티바이러스 벡터의 용도
JP4804356B2 (ja) 第ＶＩＩＩ因子及びその誘導体の高発現レベルのための改変されたｃＤＮＡ
MXPA01005667A (en) Expression system for factor viii
RU2429294C2 (ru) ЭКСПРЕССИОННАЯ ГЕНЕТИЧЕСКАЯ КОНСТРУКЦИЯ pOptivec/F8BDD, КОДИРУЮЩАЯ РЕКОМБИНАНТНЫЙ ФАКТОР СВЕРТЫВАЕМОСТИ КРОВИ VIII ЧЕЛОВЕКА С ДЕЛЕЦИЕЙ В-ДОМЕНА, И КЛЕТОЧНАЯ ЛИНИЯ DG-OV-F8BDD-18, ПРОДУЦИРУЮЩАЯ РЕКОМБИНАНТНЫЙ ФАКТОР СВЕРТЫВАЕМОСТИ КРОВИ VIII ЧЕЛОВЕКА С ДЕЛЕЦИЕЙ В-ДОМЕНА
NO300428B1 (no) Fremgangsmåte ved fremstilling av proteiner med FVIII aktivitet eller FVIII derivater
US20020177544A1 (en) Adenoviral transfer vector for the gene transport of a dna sequence
DK168713B1 (da) Fremgangsmåde til fremstilling af proteiner med FVIII (Faktor VIII) aktivitet og/eller FVIII derivater

Legal Events

Date Code Title Description
MK4A Expiry of patent

Expiry date: 20191208